Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

Leishmaniasis, Cutaneous Clinical Trial

Official title:

Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03762070
• Other study ID #: LRDD-PERU-02
• Status: Recruiting
• Start date: October 2, 2018
• Est. completion date: April 2019

Study information

• Verified date: November 2018
• Source: Naval Medical Research Center
• Contact: Max Grogl, Ph.D.
• Phone: 51-1-614-4159
• Email: max.grogl1.civ[@]mail.mil
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test in Peru, using a test procedure that was modified from that described in the device instructions to optimize these parameters for the detection of Leishmania species identified in Peru.

Description:

Observational study of a FDA cleared device, the CL Detect™ Rapid Test. Data for the 510(K) was supported by a sensitivity study conducted in Tunisia, Old world Leishamania major and a specificity study conducted in the United Sates. Sensitivity and specificity data collected recently in Peru (2014-2015), by the Instituto de Medicina Tropical Alexander von Humbolt, supports the idea that the sensitivity of the CL Detect™ Rapid Test can be drastically increased for New World Leishmania species. The study is a single trial, with two clinical sites, NAMRU-6, Puerto Maldonado and the Alexander von Humboldt Tropical Medicine Institute in Lima. The objective of the study is to determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test, using an optimized test procedure determined from a pilot study conducted in Peru. Two modifications to the test procedure (marketed device instructions) are included in this study: 1) increase in extraction time in lysis buffer from 5 to 10 minutes to 20 to 30 minutes and 2) a 20 μl increase in the volume of the sample to add to the test strip, from 20 μl to 40 μl. The gold standard for Leishmania diagnosis, which is microscopic identification of amastigotes in stained lesion sample, will be used as a control.

Participants will be patients who present for medical consultation due to a suspected CL lesion. After obtaining informed consent and screening the participant for eligibility, we will collect and test at most 4 samples from the index lesion in the following order:

1. one sample obtained with a dental broach for use with the CL Detect™ Rapid Test;

2. one sample obtained by scraping for microscopic identification of amastigotes; and

3. one sample obtained by scraping for Leishmania speciation by PCR; and

4. when possible, (depending on the size of the lesion), one sample from a different site of the same lesion, obtained by scraping for use with the CL Detect™ Rapid Test. PCR analysis will be performed by NAMRU-6 for possible exploratory analyses including species identification. If the etiologies of the lesions that are negative for Leishmania are known, they will be reported. Participants with a positive diagnosis of leishmaniasis by microscopy or other methods will be referred for standard of care treatment in Peru by the attending physician of the Peruvian Ministry of Health. Treatment is not part of this study. If a participant's lesions are negative for Leishmania, standard of care follow-up testing will be performed, either at the study site, or (when indicated) in another hospital.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: April 2019
• Est. primary completion date: March 2019
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age and generally healthy.

• Able to provide written informed consent.

• Index lesion present that is suspicious for CL, as defined by the following criteria for an index lesion:

1. less than 2 months in age

2. primarily ulcerative, i.e. not purely verrucous or nodular

3. no clear clinical evidence of cellulitis

4. location suitable for collecting samples by dental broach and scraping.

• Capable of understanding and complying with the protocol, in the opinion of the evaluator

Exclusion Criteria:

• Received treatment for leishmaniasis within the last 2 months prior to evaluation.

• In the opinion of the investigator, evidence of manipulation of the lesion.

Related Conditions & MeSH terms

• Leishmaniasis
• Leishmaniasis, Cutaneous

Intervention

Device:
• CL Detect™ Rapid Test
Observational study of a FDA cleared device, the CL Detect™ Rapid Test.

Locations

Country	Name	City	State
Peru	Universidad Peruana Cayetano Heredia (UPCH)	Lima
Peru	U.S. Naval Medical Research Center Unit No. 6 (NAMRU-6)	Puerto Maldonado

Sponsors (1)

Lead Sponsor	Collaborator
Naval Medical Research Center

Country where clinical trial is conducted

Peru, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The performance (sensitivity and specificity) of the CL Detect™ Rapid Test	Sensitivity and specificity of CL Detect™ Rapid Test will be determined by comparing with the gold standard, microscopy of stained lesion samples for identification of Leishmania amastigotes. The following definitions apply to the calculation of assay sensitivity and specificity: 1. True positive: Positive by both the CL Detect™ Rapid Test and the reference method. 2. False positive: Positive by the CL Detect™ Rapid Test but negative for the reference method. 3. True negative: Negative by both the CL Detect™ Rapid Test and the reference method. 4. False negative: Negative by the CL Detect™ Rapid Test but positive for the reference method.	1 day
Secondary	Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test when scraping is used to obtain tissue samples.	Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test when scraping is used to obtain tissue samples.	1 day